Marcu Cristina, Schiffer Eduardo, Aubert John-David, Vionnet Julien, Yerly Patrick, Deltenre Pierre, Marot Astrid
Service de gastroentérologie et d'hépatologie, CHUV, 1011 Lausanne.
Service d'anesthésie, Département APSI, HUG, 1211 Genève 14.
Rev Med Suisse. 2017 Aug 30;13(572):1464-1469.
Hepatopulmonary syndrome (HPS) and portopulmonary hypertension (POPH) are two frequent pulmonary complications of liver disease. Portal hypertension is a key element in the pathogenesis of both disorders, which are however distinct in terms of pathogenesis, diagnosis and treatment. HPS corresponds to an abnormal arterial oxygenation in relation with the development of intrapulmonary vascular dilatations. POPH is a pulmonary arterial hypertension in the setting of portal hypertension and elevated pulmonary vascular resistance. As both diseases are associated with an increased risk of morbidity and mortality, it is important to screen and evaluate the severity of these two disorders particularly in liver transplant candidates.
肝肺综合征（HPS）和门脉性肺动脉高压（POPH）是肝病常见的两种肺部并发症。门脉高压是这两种病症发病机制中的关键因素，然而，它们在发病机制、诊断和治疗方面有所不同。HPS与肺内血管扩张相关的动脉氧合异常有关。POPH是在门脉高压和肺血管阻力升高情况下的肺动脉高压。由于这两种疾病都与发病率和死亡率增加相关，因此对这两种病症进行筛查和评估严重程度非常重要，尤其是对于肝移植候选者。
